FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

1172797009: Teneligliptin hydrobromide (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Sep 2021. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
4636049012 Teneligliptin hydrobromide (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
4636050012 Teneligliptin hydrobromide en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Teneligliptin hydrobromide (substance) Is a Enzyme inhibitor false Inferred relationship Some
Teneligliptin hydrobromide (substance) Is a Dipeptidyl peptidase IV inhibitor true Inferred relationship Some
Teneligliptin hydrobromide (substance) Is a Carboxylic acid and/or carboxylic acid derivative (substance) true Inferred relationship Some
Teneligliptin hydrobromide (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Dipeptidyl peptidase IV inhibitor (disposition) true Inferred relationship Some
Teneligliptin hydrobromide (substance) This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Teneligliptin (substance) true Inferred relationship Some
Teneligliptin hydrobromide (substance) Is a A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them. true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely teneligliptin (as teneligliptin hydrobromide) 20 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Teneligliptin hydrobromide (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start